Skip to content

PolitiKit

Lobbying by Best Medicines Coalition: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Client of a consultant lobbyist

Best Medicines Coalition

Meetings this Parliament
2
With MPs
0
Since Nov 2021
2
Active registrations
1

Most recent reported meeting: Oct 6, 2026.

Registrations in effect

Consultant In effect since Jul 14, 2026

Consultant Brittany Barnes

Consultant lobbyists

  • Brittany Barnes

Institutions they may lobby: Employment and Social Development Canada (ESDC), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), Office of the Auditor General of Canada (OAG), Office of the Public Sector Integrity Commissioner (PSIC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Safety Canada (PS), Public Services and Procurement Canada (PSPC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS)

What they're lobbying on (9)
  • Provide insight and feedback on the pharmacare program in the areas of accessibility, uses and recommendations on behalf of the coalition.
  • Support input regarding the Pharmaceutical and Life Sciences Sector Task Force.
  • Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB.
  • Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.
  • Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.
  • Provide input on a national strategy for drugs for rare diseases.
  • Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.
  • Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency.
  • Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States.

Registration 965845-387183-1. Look it up in the official Registry

Reported meetings

Spreadsheet

  • Reported by Brittany Barnes · Consultant

    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines. Read more

    Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.

    Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB.

    Official report

  • Reported by Brittany Barnes · Consultant

    • Justine Frame · Policy Advisor, Health Canada (HC)
    Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency. Read more

    Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.

    Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.

    Support input regarding the Pharmaceutical and Life Sciences Sector Task Force.

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.